Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion

Neurobiology of Aging

Volumn 24, Issue 3, 2003, Pages 491-500

  Khaldy, Hoda ^a   Escames, Germaine ^a   León, Josefa ^a   Bikjdaouene, Leila ^a   Acuña Castroviejo, Darío ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Deprenyl; Dopamine; Electron transport chain; Melatonin; Mitochondrial complex I; MPTP; Oxidative stress; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATECHOLAMINE; DOPAMINE; MELATONIN; MITOCHONDRIAL COMPLEX I; MITOCHONDRIAL ENZYME; NEUROTOXIN; SELEGILINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; CATECHOLAMINE BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ELECTRON TRANSPORT; ENZYME ACTIVITY; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIOXIDANTS; DOPAMINE; DRUG SYNERGISM; FREE RADICAL SCAVENGERS; LIPID PEROXIDATION; MALE; MELATONIN; MICE; MICE, INBRED STRAINS; MITOCHONDRIA; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; SELEGILINE; TYROSINE 3-MONOOXYGENASE;

EID: 0037405378     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00133-1     Document Type: Article

References (55)

1. +-induced inhibition of complex I of the mitochondrial respiratory chain. J. Pineal Res. 29:2000;40-47.
2. Acuna-Castroviejo D., Escames G., Carazo A., León J., Khaldy H., Reiter R.J. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr. Top. Med. Chem. 2:2002;133-151.
3. Acuña-Castroviejo D., Escames G., Mias M., Muñoz-Hoyos A., Molina-Carbailo A., Arauzo M.et al. Cell protective role of melatonin in the brain. J. Pineal Res. 19:1995;57-63.
4. Acuña-Castroviejo D., Coto-Montes A., Monti M.G., Ortiz G.G., Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocamoal lesions. Life Sci. 60:1997;23-29.
5. Acuña-Castroviejo D., Martín M., Macías M., Escames G., León J., Khaldy H.et al. Melatonin, mitochondria and cellular bioenergetics. J. Pineal Res. 30:2001;65-74.
6. Aguiar L.M.V., Vasconcelos S.M.M., Sousa F.C.F., Viana G.S.B. Melatonin reverses neurochemical alterations induced by 6-OHDA in rat striatum. Life Sci. 70:2002;1041-1051.
7. Alexiuk N.A.M., Uddin M., Vriend J. Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Life Sci. 59:1996;687-694.
8. Annepu J., Ravindranath V. MPTP induced complex I inhibation is reversed by disulfite reductant, dithiothreotol in mouse brain. Neurosci. Lett. 289:2000;209-212.
9. Antolín I., Rodríguez C., Sainz R.M., Mayo J.C., Uria H., Kotler M.L.et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J. 10:1996;822-890.
10. Betarbet R., Sherer T.B., MacKenzie G., García-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
11. Blandinni F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuity in Parkinson's disease. Prog. Neurobiol. 62:2000;63-88.
12. Blank C.L., Pike R. Anoval inexpensive and sensitive method for analysis of tyrosine hydroxylase activity in tissue sample. Life Sci. 18:1976;859-866.
13. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitchomdria via an oxidative mechanism. Biochem. Biophys. Acta. 1453:1999;49-62.
14. +-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J. Pineal. Res. 32:2002;262-269.
15. Chiueh C.C., Hitoshi M., Ming-Tsun P. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanism involved in MPTP-induced Parkinsonism. Adv. Neurol. 60:1993;251-257.
16. Crespo E., Macías M., Pozo D., Escames G., Martín M., Vives F.et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysacharide-induced multiple organ dysfunction syndrome in rats. FASEB J. 13:1999;1537-1546.
17. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15:2001;164-170.
18. Escames G., Acuña-Castroviejo D., Vives-Montero F. Melatonin-dopamine interaction in the striatal projection area of sensory motor cortex in the rat. Neuroreport. 7:1996;597-600.
19. Escames G., Guerrero J.M., Reiter R.J., García J.J., Muñoz-Hoyos A., Ortiz G.G.et al. Melatonin and vitamin E limit nitric oxide-induced lipid peroxidation in rat brain homogenates. Neurosci. Lett. 230:1997;147-150.
20. Estornell E., Fato R., Pallotti F., Lenaz G. Assay conditions for the mitochondrial NADH: coenzyme Q oxidoreductase. FEBS Lett. 332:1993;127-131.
21. 2 and ATP production and on dopamine and DOPAC in the striatum. J. Physiol. Biochem. 55:1999;325-332.
22. García J.J., Reiter J.R., Pié J., Ortiz G.G., Cabrera J., Sainz R.M.et al. Role of pinoline and melatonin in stabilizing hepatic microsomal membranes against oxidative damage. J. Bioenerg. Biomembr. 31:1999;609-616.
23. + and 4-phenyl pyridine analogs in inner membrane preparations. J. Biol. Chem. 269:1994;3167-3174.
24. Gilgun-Sherki Y., Melamed E., Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology. 40:2001;959-975.
25. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of MPTP in mice. Science. 224:1984;1451-1453.
26. Heinonen E.H., Lammintausta R. A review of pharmacology of selegiline. Acta Neurol. Scand. 136:1991;44-59.
27. Hovius R., Lambrechts H., Nicolay K., de Kruijff B. Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane. Biochem. Biophys Acta. 1021:1990;217-226.
28. Iacovitti L., Stull N.D., Johnston K. Matonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res. 768:1997;317-326.
29. Itzhak Y., Martin L.J., Black M.D., Ali S.F. Effect of melatonin on methanphetamine and MPTP induced dopaminergic neurotoxicity and metamphetainine induced behavioural sensitization. Neuropharmacology. 37:1998;781-791.
30. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T.et al. Glutathione depletion in PC12 cells results in selective inhibition of mitochondrial complex I activity. implications for Parkinson's disease. J. Biol. Chem. 275:2000;26096-26101.
31. + neurotoxicity in rat. Neurosci. Lett. 245:1998;61-64.
32. Khaldy H., Escames G., León J., Vives F., Luna J.D., Acuña-Castroviejo D. Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl formation during dopamine autoxidation in vitro. J. Pineal Res. 24:2000;215-218.
33. Khaldy H., León J., Escames G., Martín M., Macías M., Acuña-Castroviejo D. Circadian rhythm of dopamine and their metabolites in mouse striatum: effects of pinealectomy and melatonin replacement. Neuroendocrinology. 75:2002;201-208.
34. Kitani K., Kanai S., Ivy G.O., Carrillo M.C. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech. Aging Dev. 111:1999;211-221.
35. Li X.-J., Gu J., Lu S.-D., Sun F.-Y. Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. J. Pineal Res. 32:2002;47-52.
36. Lowry O.H., Rosebrough A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-268.
37. Martín M., Macías M., Escames G., León J., Acuña-Castroviejo D. Melatonin but not vitamin C and D maintains gluthatione homeostasis in t-buthyl hydroperoxide induced mitochondrial oxidative stress. FASEB J. 14:2000;1677-1679.
38. Martín M., Macías M., Escames G., Reiter R.J., Agapito M.T., Ortiz G.G.et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J. Pineal Res. 28:2000;242-248.
39. Martín M., Macías M., León J., Escames G., Khaldy H., Acuña-Castroviejo D. Melatonin increases the activity of the complexes I and IV of the electron transport chain and the ATP production in rat brain and liver mitochondria. Int. J. Biochem. Cell. Biol. 1212:2001;1-10.
40. Maruyama W., Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech. Aging Dev. 111:1999;189-200.
41. Menéndez-Peláez A., Reiter R.J. Distribution of melatonin mammalian tissues: The relative importance of nuclear versus cytosolic localization. J. Pineal Res. 15:1993;59-69.
42. Nakamura K., Bindokas V.P., Marks J.D., Wright D.A., Frim D.M., Miller R.J.et al. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the roles of mitochondrial complex I and reactive oxgyen species revised. Mol. Pharmacol. 58:2000;271-278.
43. Orth M., Schapira A.H.V. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40:2002;533-541.
44. Ortiz G.G., Crespo López B., Morán-Mogul C., García J.J., Reiter R.J., Acuña-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocr. Lett. 22:2001;101-108.
45. Reilly C.E. Glial cell line-derived neurotrophic factor (GDNF) prevents neurodegneration in models of parkinson's disease. J. Neurol. 248:2001;76-78.
46. Reiter R.J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J.et al. A review of the evidence supporting melatonin's role as antioxidant. J. Pineal Res. 18:1995;1-11.
47. Reiter R.J., Guerrero J.M., Escames G., Papolla M.A., Acuña-Castroviejo D. Prophylactic actions of melatonin in oxidative neurotoxicity. Ann. NY Acad. Sci. 825:1997;70-78.
48. Reiter R.J., Tan D.X., Acuña-Castroviejo D., Burkhardt S., Karbownik M. Melatonin: mechanisms and actions as an antioxidant. Curr. Top. Biophys. 24:2000;171-183.
49. Rodríguez-Gómez J.A., Venero J.L., Vizuete M.L., Cano J., Machado A. Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system. Mol. Brain Res. 46:1997;31-38.
50. + induced efflux of dopamine and lactate from rat striatum have similar time curse as shown by in vivo brain dialysis. Eur. J. Pharmacol. Exp. Ther. 245:1988;858-866.
51. Seaton T.A., Cooper J.M., Schapira A.H.W. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777:1997;110-118.
52. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T.et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 253:1998;614-620.
53. Tan D.X., Manchester R.J., Reiter R.J., Plumer B.F., Limson J., Weintraub S.T.et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic. Biol. Med. 29:2000;1177-1185.
54. Tang Y.P., Ma Y.L., Chao C.C., Chen K.Y., Lee E.H. Enhanced cell line derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. 53:1998;593-604.
55. Tatton W.G., Greenwood C.G. Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J. Neurosci. Res. 30:1991;666-672.